Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos

Luis Malpica(The University of Texas MD Anderson Cancer Center), Brady Beltrán(The University of Texas MD Anderson Cancer Center)

JCO Global Oncology

July 16, 2021

10.1200/go.21.00084

Cited by 32

Related Papers

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

|The Lancet Oncology|2023|55